Boston Scientific Corporation $BSX Shares Sold by Rhumbline Advisers

Rhumbline Advisers lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 0.4% in the 3rd quarter, Holdings Channel reports. The fund owned 2,726,293 shares of the medical equipment provider’s stock after selling 11,332 shares during the quarter. Rhumbline Advisers’ holdings in Boston Scientific were worth $266,168,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. State Street Corp raised its holdings in shares of Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after buying an additional 713,379 shares during the period. Synergy Asset Management LLC lifted its holdings in shares of Boston Scientific by 3,493.0% in the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after buying an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC increased its stake in Boston Scientific by 39.5% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after purchasing an additional 14,700 shares in the last quarter. Channel Wealth LLC boosted its position in shares of Boston Scientific by 70.8% in the 3rd quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock worth $2,790,000 after buying an additional 11,847 shares in the last quarter. Finally, Bank of Nova Scotia lifted its holdings in shares of Boston Scientific by 106.4% in the second quarter. Bank of Nova Scotia now owns 3,025,519 shares of the medical equipment provider’s stock valued at $324,971,000 after purchasing an additional 1,559,605 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Boston Scientific stock opened at $74.26 on Wednesday. The stock has a fifty day moving average price of $92.36 and a two-hundred day moving average price of $98.24. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific Corporation has a 52-week low of $73.92 and a 52-week high of $109.50. The firm has a market capitalization of $110.09 billion, a P/E ratio of 38.28, a P/E/G ratio of 1.55 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of several analyst reports. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a research note on Friday. Morgan Stanley reduced their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. TD Cowen cut their price objective on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Oppenheimer reduced their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a report on Friday, January 16th. Finally, Mizuho lowered their target price on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $109.43.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.